Compare APC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | EVO |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.8M | 934.1M |
| IPO Year | N/A | N/A |
| Metric | APC | EVO |
|---|---|---|
| Price | $19.36 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $21.75 | $7.00 |
| AVG Volume (30 Days) | ★ 102.0K | 95.4K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.47 | $1.37 |
| Revenue Next Year | $4.20 | $10.05 |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.08 | $2.31 |
| 52 Week High | $19.80 | $4.80 |
| Indicator | APC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 52.19 |
| Support Level | $18.33 | $2.88 |
| Resistance Level | $19.76 | $3.78 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 94.51 | 33.33 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.